Navigation Links
Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
Date:8/30/2011

organization, enthusiasm of Pearl's clinical investigators, and our overall commitment to capital efficiency while generating high quality clinical data. In the next few months, we look forward to presenting results from the remaining three studies in our ongoing Phase 2b program, which is funded by our 2010 Series C financing. We intend to meet with the FDA in the first half of 2012, in preparation for PT003 registrational studies targeted to start in late 2012."

About COPD

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable lung disease that is the fourth leading cause of death in the United States. Each year 12 million Americans are diagnosed with COPD and an additional 12 million Americans may have COPD but remain undiagnosed. Research shows that many do not get optimal treatment.

Bronchodilator medications are central to symptom management and are prescribed on an as-needed or regular basis to prevent or reduce symptoms. Long-acting inhaled bronchodilators have been shown to be most effective and convenient. Combining bronchodilators of different pharmacological classes, as recommended by The Global Initiative for Chronic Obstructive Lung Diseases (GOLD), has been shown to improve efficacy and may decrease the risk of side effects compared to increasing the dose of a single bronchodilator. As the course of COPD progresses, regular treatment with inhaled glucocorticosteroids may be added to bronchodilator treatment. Pearl is developing inhaled combination products designed to optimize the treatment of COPD.

About Pearl Therapeutics

Pearl Therapeutics is a privately held company developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease and asthma. Pearl is rapidly advancing a pipeline of products including PT003, an inhaled, fixed-dose combination
'/>"/>

SOURCE Pearl Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
2. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
3. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
4. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
5. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
6. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
7. Prime Therapeutics Drug Trend Insights Reports One of the Lowest Drug Spending Increases in the Industry
8. Precision Therapeutics Named on Inc. 500
9. 5000 2011 List and Recognized for Achievements in Personalized Medicine Industry
10. Cell Therapeutics Submits Day 120 Response for Pixantrone Marketing Authorization Application to European Medicines Agency; Potential Q1 2012 Opinion on Approval
11. Inhibikase Therapeutics Receives FDA Clearance for Phase II Trial of IkT-001 to Treat JC Virus Infection, the Cause of Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... DIEGO , May 4, 2015 ... oncology company focused on the clinical development of ... data showing mitochondria-specific effects of the Company,s investigational ... enhanced anti-tumor activity when combined with a tyrosine-kinase ... found ME-344 to be a potent inhibitor of ...
(Date:5/4/2015)... the cuvette manufacturing world, opened their doors to the public in early 2015.  In ... scientists amazing support for their spectroscopy needs.  ... ... ... In mid-2014 Simcha Woitovich ...
(Date:5/4/2015)... May 4, 2015 Dyadic International, Inc. ... patented and proprietary technologies are used to develop, ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme ... financial results for quarter ending March 31, 2015 ... and will host a conference call that day ...
Breaking Medicine Technology:MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 2New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 3Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 3
(Date:5/4/2015)... Washington, DC (PRWEB) May 04, 2015 ... of Kit Check as a finalist for the EY ... Washington Region. The awards program recognizes entrepreneurs who ... innovation, financial performance and personal commitment to their businesses ... finalist by a panel of independent judges. Award ...
(Date:5/4/2015)... Ticket Down is a reputable source for ... in Columbia, South Carolina. Fans of Paul McCartney ... There” tour which originally kicked off in 2013. The most ... and the legendary performer recently announced that he would be ... on June 21st, in Charlottesville, VA at John Paul Jones ...
(Date:5/4/2015)... San Diego Fertility Center (SDFC) ... new, 13,700 square foot facility scheduled to open in ... only provide fertility treatment and services for the center’s ... educational events to a number of local and international ... to their current Carmel Valley/Del Mar location and will ...
(Date:5/4/2015)... Rafael, CA (PRWEB) May 04, 2015 Unlike some ... foremost on imparting knowledge. The goal is to educate first ... the classroom. This ensures that the young runners are building ... careers. A few of the topics covered include Effort Based ... fast as I used to be? This is not a ...
(Date:5/4/2015)... May 04, 2015 Sylvia Hawthorn-Deppen shared her ... that it would remind others in similar situations that they ... from Chronic Pain and Discovery of New Energy” (published by ... new audience via a renewed press campaign. , “I have ... debilitating pain ,” Hawthorn-Deppen says. “As an adolescent I got ...
Breaking Medicine News(10 mins):Health News:EY announces Kit Check CEO and Co-founder Kevin MacDonald as an EY Entrepreneur Of The Year® 2015 Award finalist in the Greater Washington Region 2Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:Author launches new press campaign for 2012 book ‘Wheel’ 2
... Nov. 21 Attorneys representing consumers and,third-party payers ... healthcare services giant McKesson (NYSE: MCK ... price of more than 400 prescription drugs by,manipulating ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080317/AQM144LOGO ) , ...
... 21 DATATRAK,International, Inc. (Nasdaq: DATA ... eClinical solutions for the clinical trials industry, today ... Corporation, has placed its first,self-designed project using the ... trial. The successful rollout of this first,independently ...
... VICL ) today announced a strategic restructuring ... the company,s total workforce,and accelerated closure of a research ... employees and expects to reduce future,net losses and cash ... The restructuring is designed to ...
... to a relationship between erectile dysfunction and prostate enlargement. Because of ... to increase the treatment of BPH in men. The focus of ... (ED). Dr. Eid will continue with ED treatments while building his ... ...
... prestigious "Super Dentist" award given to elite dentists in Texas. Dr. ... in the area of Cosmetic Dentistry. , ... Austin, ... Smiles was recently nominated as a "Texas Monthly Super Dentist" ...
... that timing is everything, and that certainly appears to be ... before the height of cold and flu season have a ... any other time of year, according to new research. ... more than 95,000 children and their mothers in Tennessee to ...
Cached Medicine News:Health News:Hagens Berman Sobol Shapiro: McKesson Settles RICO Lawsuit for $350 Million 2Health News:Hagens Berman Sobol Shapiro: McKesson Settles RICO Lawsuit for $350 Million 3Health News:NTT DATA Launches First Self-Designed DATATRAK eClinical(TM) Project Into Production in Japan 2Health News:NTT DATA Launches First Self-Designed DATATRAK eClinical(TM) Project Into Production in Japan 3Health News:Vical Announces Strategic Restructuring and Staff Reduction 2Health News:Vical Announces Strategic Restructuring and Staff Reduction 3Health News:World-Renowned Urologist, J. Francois Eid, M.D., Expands Practice with Increased Treatment of Benign Prostate Hyperplasia (BPH) 2Health News:World-Renowned Urologist, J. Francois Eid, M.D., Expands Practice with Increased Treatment of Benign Prostate Hyperplasia (BPH) 3Health News:World-Renowned Urologist, J. Francois Eid, M.D., Expands Practice with Increased Treatment of Benign Prostate Hyperplasia (BPH) 4Health News:Texas Super Dentist Awards Announced--Dr. Michael McCarty From Austin Smiles Is Awarded For The Third Year In A Row 2Health News:Fall babies: Born to wheeze? 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: